INSM - NASDAQ

Insmed Incorporated

Insmed Incorporated

INSMยทNASDAQ

$103.86

+0.13%
HealthcareBiotechnology

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$22.51B
EPS-6.4100
P/E Ratio-16.20
Earnings Date08/06/2026
Insmed Incorporated

Insmed Incorporated Fair Value Envelope

INSM ยท NASDAQ

Our analysis suggests that INSM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $103.86, this represents a potential HIDDEN relative to our calculated worth for Insmed Incorporated.

HIDDEN
Intrinsic Value
Current Price: $103.86

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.3B
+ Cash & Equivalents$510.4M
Firm Value-$797.4M
- Debt$768.2M
Equity Value-$1.6B
/ Shares Outstanding213,273,469B
DCF Value-$7
OVERVALUED BY 107%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$588.2M
-$370.1M
-$232.8M
-$146.5M
-$92.1M
-$58.0M
-$36.5M
-$22.9M
-$14.4M
-$9.1M
Maintenance CapEx
-$4.1M
-$2.6M
-$1.6M
-$1.0M
-$641.8K
-$403.8K
-$254.0K
-$159.8K
-$100.5K
-$63.2K
Owner Earnings
-$592.3M
-$372.6M
-$234.4M
-$147.5M
-$92.8M
-$58.4M
-$36.7M
-$23.1M
-$14.5M
-$9.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$548.5M
-$319.5M
-$186.1M
-$108.4M
-$63.2M
-$36.8M
-$21.4M
-$12.5M
-$7.3M
-$4.2M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your INSM research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.